This study provides evidence to support the use of early anti-TNF therapy in paediatric patients with newly diagnosed Crohn’s disease, in particular in presumed high-risk patients, ie, those with moderate-to severe disease activity or the presence of any POPO. This evidence concerns the gene TNF and Crohn disease.